News Releases

Apr 21, 2016
OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting

REDWOOD CITY, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present data from several clinical programs at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.

Presentations include the first clinical data of OncoMed's Wnt pathway inhibitors (vantictumab and ipafricept) in combination therapy.  The Phase 1b vantictumab (anti-Fzd7, OMP-18R5) clinical trial is in combination with paclitaxel in breast cancer and the Phase 1b ipafricept (FZD8-Fc, OMP-54F28) clinical trial is in combination therapy with carboplatin and paclitaxel in ovarian cancer.

In addition, updated survival data from OncoMed's Phase 1b clinical trials of demcizumab (OMP-21M18, anti-DLL4) in non-small cell lung cancer (NSCLC) and of tarextumab (anti-Notch2/3, OMP-59R5) in small cell lung cancer will be presented.

A complete list of OncoMed's accepted abstracts is provided below.

Poster Discussions

Saturday, June 4, 3:00pm - 4:15pm CT at E354b

1. Abstract #9023: A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM), Pemetrexed (PEM) & Carboplatin (CARBO) in Patients (pts) with 1st Line Non-Squamous NSCLC

Presenter: Mark James McKeage, MBChB, MMedSc, PhD, FRACP, Auckland City Hospital and University of Auckland
Session: Lung Cancer - Non-Small Cell Metastatic
Poster Display: Hall A; Poster Board#346; 8:00 am - 11:30am CT

Sunday, June 5, 11:30am - 12:45pm CT at Arie Crown Theater

2. Abstract #2515: Phase 1b of WNT inhibitor Ipafricept (IPA, decoy receptor for WNT ligands) with Carboplatin (C) and Paclitaxel (P) in Recurrent Platinum-Sensitive Ovarian Cancer (OC)

Presenter: Roisin E. O'Cearbhaill, M.D., Memorial Sloan Kettering Cancer Center
Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Poster Display:  Hall A; Poster Board #215; 8:00am - 11:30am CT

3. Abstract #2516: Phase 1b Study of WNT Inhibitor Vantictumab (VAN, human monoclonal antibody) with Paclitaxel (P) in Patients (pts) with 1st- to 3rd-Line Metastatic HER2-Negative Breast Cancer (BC)

Presenter: Monica Mita, MD, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute
Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Poster Display: Hall A; Poster Board #216; 8:00am - 11:30am CT


Saturday, June 4, 8:00am — 11:00am CT

Abstract #8564: Updated results of Phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
Lead author: Anne Chiang, M.D., Ph.D., of the Yale School of Medicine
Session: Lung Cancer — Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Location: Hall A; Poster Board#192

About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics.  OncoMed has seven anti-cancer therapeutic candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR.  OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate (IO#2) toward clinical trials in the 2016-2017 timeframe.  OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). 

Additional information can be found at the company's website:

Michelle Corral
Senior Director, Investor Relations and Corporate Communications
OncoMed Pharmaceuticals 
(650) 995-8373


OncoMed Pharmaceuticals, Inc. is a wholly-owned subsidiary of Mereo BioPharma Group plc.
Please visit our parent site for our Pipeline, Partnering Opportunities and Investors information.